Eli Lilly's new obesity pill makes strong debut

Name: Eli Lilly's new obesity pill makes strong debut
Uploaded: 2026-04-17T20:07:56Z
Duration: 38 s
Description: Eli Lilly's stock is up almost 2% after its new obesity pill, Zepbound (Foundayyo), was prescribed nearly 1,400 times in its debut week in the US. In comparison, rival Novo Nordisk's obesity pill saw over 3,000 prescriptions in its first four days, but its stock is currently lower.

The Claman Countdown · FBN · Apr 17, 2026 · 38s

Sign Up Now

Already a subscriber?

Eli Lilly's stock is up almost 2% after its new obesity pill, Zepbound (Foundayyo), was prescribed nearly 1,400 times in its debut week in the US. In comparison, rival Novo Nordisk's obesity pill saw over 3,000 prescriptions in its first four days, but its stock is currently lower.